We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.32%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
-$11.8M
Cap. Flow
-$571K
Cap. Flow %
-0.02%
Top 10 Hldgs %
40.31%
Holding
207
New
13
Increased
45
Reduced
58
Closed
10

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.47M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.05M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.91M
4
BSX icon
Boston Scientific
BSX
+$6.1M
5
GILD icon
Gilead Sciences
GILD
+$5.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.7M
2
ILMN icon
Illumina
ILMN
+$12.7M
3
ELV icon
Elevance Health
ELV
+$10.4M
4
CNC icon
Centene
CNC
+$6.81M
5
AGN
Allergan plc
AGN
+$6.78M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Real Estate 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
26
DELISTED
Allergan plc
AGN
$24.2M 0.99%
144,281
-48,982
-25% -$6.78M
DHR icon
27
Danaher
DHR
$137B
$22.7M 0.93%
179,274
– –
SRPT icon
28
Sarepta Therapeutics
SRPT
$1.57B
$22.5M 0.92%
147,847
– –
SYK icon
29
Stryker
SYK
$125B
$21.2M 0.86%
102,950
-20,100
-16% -$3.84M
BMRN icon
30
BioMarin Pharmaceuticals
BMRN
$11.6B
$21.1M 0.86%
245,763
+23,677
+11% +$2.03M
SGEN
31
DELISTED
Seagen Inc. Common Stock
SGEN
$20.1M 0.82%
289,925
– –
CI icon
32
Cigna
CI
$73.8B
$18.4M 0.75%
116,756
– –
VTRS icon
33
Viatris
VTRS
$20.4B
$18M 0.73%
943,152
– –
NBIX icon
34
Neurocrine Biosciences
NBIX
$16.8B
$17.5M 0.71%
207,078
-14,600
-7% -$1.2M
IDXX icon
35
Idexx Laboratories
IDXX
$44.1B
$17M 0.69%
61,754
-1,900
-3% -$468K
SAGE
36
DELISTED
Sage Therapeutics
SAGE
$15.4M 0.63%
84,145
+4,289
+5% +$732K
PRAH
37
DELISTED
PRA Health Sciences, Inc.
PRAH
$15.2M 0.62%
153,003
+9,466
+7% +$903K
ARRY
38
DELISTED
Array Biopharma Inc
ARRY
$15M 0.61%
323,883
-40,283
-11% -$1.13M
BDX icon
39
Becton Dickinson
BDX
$45.6B
$14.7M 0.6%
59,899
-3,365
-5% -$782K
EXEL icon
40
Exelixis
EXEL
$13.3B
$14.5M 0.59%
678,467
– –
BAX icon
41
Baxter International
BAX
$13.5B
$14.5M 0.59%
176,698
+39,030
+28% +$3.03M
AZN icon
42
AstraZeneca
AZN
$263B
$13.8M 0.56%
167,499
-13,000
-7% -$1.02M
BLUE
43
DELISTED
bluebird bio
BLUE
$13M 0.53%
7,868
+841
+12% +$1.45M
EW icon
44
Edwards Lifesciences
EW
$49.6B
$12.9M 0.53%
209,307
+38,913
+23% +$2.35M
MCK icon
45
McKesson
MCK
$100B
$12.9M 0.52%
95,691
+24,971
+35% +$3.11M
HUM icon
46
Humana
HUM
$43.7B
$12.8M 0.52%
48,122
+12,440
+35% +$3.15M
WELL icon
47
Welltower
WELL
$169B
$12.4M 0.51%
152,322
-85,000
-36% -$6.68M
NVO
48
Novo Nordisk
NVO
$208B
$12.3M 0.5%
482,000
-21,200
-4% -$524K
HCA icon
49
HCA Healthcare
HCA
$87.2B
$12.1M 0.49%
89,569
– –
COR icon
50
Cencora
COR
$60.6B
$12M 0.49%
140,273
+61,047
+77% +$4.83M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Tekla Capital Management held 207 positions worth $2.45B, down 0.48% from $2.46B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2019 filing shows 13 new, 45 increased, 58 reduced and 10 closed positions. Its largest new stake was Alcon: 55,369 shares worth $3.44M. The largest sale was Biogen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2019 buy was Alcon: 55,369 shares worth $3.44M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $8.47M increase.
  • Tekla Capital Management's biggest Q2 2019 reduction was Biogen, cutting an estimated $20.7M.
  • Tekla Capital Management fully exited Centene in Q2 2019, selling an estimated $6.81M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2019.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q2 2019.
  • Tekla Capital Management's portfolio value fell 0.48% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.